Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Non-cash Items (2017 - 2025)

Dianthus Therapeutics (DNTH) has 6 years of Non-cash Items data on record, last reported at $2.3 million in Q3 2025.

  • For Q3 2025, Non-cash Items rose 86.17% year-over-year to $2.3 million; the TTM value through Sep 2025 reached $2.3 million, up 86.17%, while the annual FY2024 figure was $24.9 million, 681.74% up from the prior year.
  • Non-cash Items reached $2.3 million in Q3 2025 per DNTH's latest filing, up from $2.2 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $24.9 million in Q4 2024 and bottomed at $699237.0 in Q3 2023.
  • Average Non-cash Items over 4 years is $4.0 million, with a median of $1.8 million recorded in 2022.
  • Peak YoY movement for Non-cash Items: plummeted 58.87% in 2023, then skyrocketed 681.74% in 2024.
  • A 4-year view of Non-cash Items shows it stood at $1.7 million in 2022, then skyrocketed by 87.12% to $3.2 million in 2023, then surged by 681.74% to $24.9 million in 2024, then crashed by 90.63% to $2.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-cash Items were $2.3 million in Q3 2025, $2.2 million in Q2 2025, and $1.8 million in Q1 2025.